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Terminal end budsith breast cancer and is required for mammary placode formation in the mouse.
In this study, we employed a genetic mosaic analysis based on Cre-mediated recombination to investigate
FGF receptor 2 (Fgfr2) function in the postnatal mammary gland. Mosaic inactivation of Fgfr2 by the MMTV-
Cre transgene enabled us to compare the behavior of Fgfr2 null and Fgfr2 heterozygous cells in the same
gland. Fgfr2 null cells were at a competitive disadvantage to their Fgfr2 heterozygous neighbors in the highly
proliferative terminal end buds (TEBs) at the invasion front, owing to a negative effect of loss of Fgfr2
function on cell proliferation. However, Fgfr2 null cells were tolerated in mature ducts. In these genetic
mosaic mammary glands, the epithelial network is apparently built by TEBs that over time are composed of a
progressively larger proportion of Fgfr2-positive cells. However, subsequently, most cells lose Fgfr2 function,
presumably due to additional rounds of Cre-mediated recombination. Using an independent strategy to
create mosaic mammary glands, which employed an adenovirus-Cre that acts only once, we conﬁrmed that
Fgfr2 null cells were out-competed by neighboring Fgfr2 heterozygous cells. Together, our data demonstrate
that Fgfr2 functions in the proliferating and invading TEBs, but it is not required in the mature ducts of the
pubertal mammary gland.
© 2008 Elsevier Inc. All rights reserved.Introduction
Branching morphogenesis is an essential developmental process
that is responsible for the formation of a variety of epithelial organs,
from the trachea and air sacs in the ﬂy to the mammary gland, lung,
kidney and salivary gland in vertebrates (Affolter et al., 2003). Unlike
branching in most other vertebrate organs, however, mammary
branching morphogenesis occurs primarily during puberty (Sternlicht
et al., 2006). Under the inﬂuence of pubertal hormones that begin
surging in mice at 3 weeks of age, a rudimentary pre-pubertal ductal
tree initiates rapid epithelial invasion and bifurcation of the terminal
end bud (TEB) at the tip of each primary duct. This process is
completed at about 9 weeks of age, when the primary ducts have
extended to the distal end of the mammary gland fat pad and the TEBs
regress. As the mammary tree extends distally, it is further elaborated
by formation of lateral (secondary) branches, which sprout from the
trailing primary ducts, as well as tertiary side-branches, until an
intricate epithelial network is established in the adult gland (Fig. 1A)
(Sternlicht et al., 2006; Wiseman and Werb, 2002).
Understanding the cellular and molecular mechanisms that
control mammary branching has been a major focus of mammary
gland biology. Several different signaling pathways, including EGFl rights reserved.(Luetteke et al., 1999; Sternlicht et al., 2005), IGF (Bonnette and
Hadsell, 2001; Ruan and Kleinberg, 1999), TGF-β (Crowley et al., 2005;
Joseph et al., 1999), Wnt (Roarty and Serra, 2007) and Hedgehog
(Lewis et al., 1999; Moraes et al., 2007) signaling, have been shown to
positively or negatively regulate this complex process [reviewed by
Hennighausen and Robinson, 2005; Lu et al., 2006b; Wiseman and
Werb, 2002]. Another candidate signaling pathway is ﬁbroblast
growth factor (FGF) signaling, which has long been associated with
breast cancer and mammary development in the mouse. In fact,
members of the FGF family, including Fgf3, Fgf4, and Fgf8 were
discovered over twenty years ago because breast tumors formedwhen
these genes were overexpressed as a consequence of mouse murine
tumor virus (MMTV) insertions (MacArthur et al., 1995; Peters et al.,
1983, 1989). Moreover, mice lacking Fgf10 fail to form mammary
placodes (Mailleux et al., 2002), thus suggesting that FGF signaling is
required for embryonic mammary gland development.
Vertebrates have four FGF receptors, FGFR1–FGFR4, that share
several evolutionarily conserved domains: three immunoglobulin
(Ig)-like extracellular domains, a transmembrane domain, and an
intracellular tyrosine kinase domain (Coumoul and Deng, 2003; Itoh
and Ornitz, 2008, 2004). Although mice lacking Fgfr2 die at
midgestation (Xu et al., 1998), before the mammary gland develops,
those that lack a speciﬁc isoform of Fgfr2, Fgfr2IIIb, survive to term but
the mammary placode fails to form, as in Fgf10 null mice (Mailleux et
al., 2002). These results thus suggest that FGF10–FGFR2IIIb signaling is
Fig. 1. Expression of FGF receptor genes in postnatal mammary glands. (A) Schematic diagrams of the developing mammary gland at the stages indicated. The terminal end buds
(TEBs) develop at the onset of puberty (3 weeks after birth) at the distal tip of each primary duct. The TEBs regress when the primary branches have extended to the distal end of the
fat pad (stroma). Proximal (Pr) is to the left and distal (Di) is to the right in this and all ﬁgures showing mammary glands in wholemount. (B–E′) Expression of Fgfr1 (B and B′), Fgfr2
(C and C′), Fgfr3 (D and D′), and Fgfr4 (E and E′) as detected by in situ hybridization with 35S-labeled probes on parafﬁn sections of mammary glands from female mice at 5 weeks of
age. (B–E) The in situ hybridization signal as viewed in dark-ﬁeld is displayed in the Photoshop red channel; DAPI staining of nuclei was viewed by ﬂuorescence, and the signal is
displayed in the Photoshop blue channel. (B′–E′) In situ hybridization signal in the samples shown in panels B–E as viewed in dark-ﬁeld. (F–H) Immunoﬂuorescence using anti-FGFR2
antibody (red, F–H) and anti-smooth muscle actin (SMA, green, F′, G′, H′) on frozen sections of mammary glands from females at the stages indicated. Samples were counterstained
with nuclear dye To-Pro3 (blue, F″,G″,H″). Arrow in panel F points to cap cells (cc). Note that a few body cells also express SMA (arrowheads in panel F′). (G, G′) Myoepithelium (me,
open arrowhead) but not luminal epithelium (le, arrow) expresses smooth muscle actin. (F‴–H‴) The FGFR2 and SMA signals are overlaid, showing co-expression in the cap cells of
the TEBs at 5 weeks (F‴) and in the myoepithelium in the ducts at 5 weeks (G‴) and 10weeks (H‴). Insets in panels F‴–H‴ are high-magniﬁcation views of the area in dashed box with
FGFR2 and nuclear signals overlaid to show that FGFR2 was mainly nuclear at 5 weeks in both ducts and TEBs (arrowheads in panels F‴ and G‴, respectively) but was mainly
cytoplasmic and at the cell surface in 10week ducts (arrowheads in panel H‴). Scale bars: 100 μm. Abbreviations: bc, body cells; cc, cap cells; lb, lateral branch; le, luminal epithelium;
me, myoepithelium.
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question of whether it is also needed in the postnatal mammary gland.
Indeed, Fgf7 and Fgf10 are expressed in the mesenchyme/stroma
during both embryonic (Mailleux et al., 2002) and postnatal develop-
ment (Kouros-Mehr andWerb, 2006; Pedchenko and Imagawa, 2000).
In culture, FGF signaling regulates a variety of cell behaviors, including
proliferation, survival, polarity, and changes in extracellular matrix
deposition that are essential for mammary branching (Fata et al.,
2007; Simian et al., 2001; Sternlicht et al., 2005; Xian et al., 2007,
2005). In this study, we have tested the hypothesis that FGF signaling
functions during branching morphogenesis in the mammary gland by
using the Cre/lox system to bypass the embryonic lethality in mice
lacking FGF receptor genes.
Materials and methods
Mouse strains
Mouse lines carrying the Fgfr2Δ and Fgfr2ﬂ alleles (Yu et al., 2003)
were kindly provided by Dr. David Ornitz. The R26R Cre-reporter line
(Soriano, 1999) was kindly provided by Dr. Philippe Soriano. Mice
carrying the MMTV-Cre transgene D line (Wagner et al., 2001) were
purchased from the Jackson Laboratory. All miceweremaintained on a
mixed genetic background. Offspring from crosses of the various lines
were genotyped according to methods in the publications describing
the mouse lines. Immunologically deﬁcient nude (nu/nu) mice were
purchased from Charles River Laboratories (strain code: 088).
Mammary gland wholemount preparation, photography and
morphometric analysis
Mammary glands #3 or #4 were harvested and mounted on glass
slides, stained with Carmine red, and cleared as described previously
(Wiseman et al., 2003). Wholemounts were photographed using a
digital camera (Nikon DXM1200) mounted on a stereo microscope
(Leica MZFL 111) and accompanying software (Nikon ACT-1). Adobe
Photoshop CS2 was used to process images and to measure ductal
penetration. Ductal penetration was the mean length of the three
longest primary epithelial branches in each mammary gland. This was
assessed by measuring the lengths of straight lines from the center of
the lymph node to the ends of those three branches (see Figs. 2C, D).
The number of branch points per millimeter of duct was the mean
number of branch points on those three longest primary ducts divided
by their mean length.
In situ hybridization analysis of mRNA, immunoﬂuorescence analysis
and staining for β-galactosidase activity
RNA in situ hybridization analysis on sections of mammary glands
was performed according to established protocols (Wiseman et al.,
2003). Probes for detection of Fgfr1 (Yamaguchi et al., 1992), Fgfr2
(Peters et al., 1992), Fgfr3 (Peters et al., 1993) and Fgfr4 (Stark et al.,
1991) RNA were prepared as reported previously. All probes were
tested on positive control samples before being used on parafﬁn
sections of the mammary gland (data not shown).
For immunoﬂuorescence analysis, mammary glands were har-
vested and ﬁxed in 4% paraformaldehyde overnight at 4 °C. 10-μm
frozen sections were cut using a Leica cryostat. Sections were blocked
for 1 h at room temperature (RT) in PBS containing 5% bovine serum
albumin and 0.5% Tween20, followed by incubation in primary an-
tibodies for 1 h at RT. Primary antibodies used in this study were anti-
FGFR2 antibody (Santa Cruz Biotechnology, sc-122, 1:200 dilution),
anti-smooth muscle actin antibody (Sigma, 1A4, 1:500 dilution), and
anti-β-galactosidase (GAL) antibody (Cappel, 55976, 1:500). Goat-
anti-rabbit Alexa 560 (Invitrogen, A11010 1:1000) was used as
secondary antibody. Samples were counterstained with To-Pro-3(Invitrogen, T3605, 1:10,000). Confocal microscopy was performed on
a Zeiss LSM510 microscope.
To assay for β-GAL activity in wholemount, mammary glands were
harvested, ﬁxed for 30 min in 4% paraformaldehyde at room
temperature, washed thoroughly in phosphate-buffered saline (PBS),
and stained overnight in LacZ (which encodes β-GAL) staining buffer
(Roche 11828673001) at 37 °C. When necessary, LacZ-stained whole-
mount mammary glands were counterstained with the ﬂuorescent
nuclear dye Yo-Yo1 (Invitrogen Y3601, 1:10,000).
Cell culture, adenovirus infection and transplantation of primary
mammary epithelium
Donor mammary glands were harvested, minced and dissociated
in buffer [10 mM Hepes buffer, 5% fetal bovine serum (FBS), RPMI
(Invitrogen 61870), Penicillin–Streptomycin 100 U/ml] containing
collagenase (Sigma C5138-1G, 2 mg/ml) for 1 h at 37 °C. Primary
epithelium was puriﬁed by ﬁve repetitions of washes in the
dissociation buffer containing no collagenase and collected using a
swinging-bucket centrifuge at 400 ×g. Puriﬁed primary mammary
epitheliumwas then resuspended in growthmedium (5 μg/ml insulin,
1 μg/ml hydrocortisone, 10 ng/ml EGF, 10% FBS, Penicillin–Streptomy-
cin 100 U/ml, Gentamicin 50 μg/ml in DMEM/F12) and infected
overnight with Adenovirus-Cre-GFP (green fluorescent protein) (He et
al., 1998) at a multiplicity of infection of ∼25 particles per cell (Rijnkels
and Rosen, 2001). The next day, organoids were washed several times
with PBS and placed in fresh growth medium. When examined under
a ﬂuorescent stereo microscope (Leica MZFL 111), ∼50–70% primary
mammary epithelial cells (MECs) appeared to be infected as indicated
by GFP expression. They were cultured for another 24 h to allow for
recovery from infection before being transplanted into cleared fat
pads of nude mice at 3 weeks of age. Recipient nude mice were
sacriﬁced 8 weeks after transplantation and mammary glands were
harvested, stained for LacZ activity, and examined on a Leica stereo
microscope (MZFL 111).
Cell proliferation and apoptosis assays
For cell proliferation analysis, mice were injected with bromo-
deoxyuridine (BrdU) (5mg/100 g bodyweight) 2 h prior to euthanasia.
Mammary glands were harvested and ﬁxed in 4% paraformaldehyde
overnight at 4 °C. 10-μm frozen sections were obtained using a Leica
cryostat. Detection of β-GAL protein and BrdU incorporation were
performed using the anti-β-GAL antibody cited above and a kit from
Roche (1296736), respectively. Antigen retrieval was performed in
10 mM sodium citrate (pH 6.0) in a microwave oven. Samples were
counterstainedwith To-Pro-3. Confocal microscopy was performed on
a LSM510 Zeiss confocal. A total of 2500–5000 cells were counted in
each mammary gland.
To assess apoptosis, frozen sections of mammary glands were
assayed for β-GAL protein and TUNEL according to manufacturer's
protocol (Roche 1684817). A total of 3000–5500 cells were counted in
each mammary gland. Alternatively, cell death was examined by
Lysotracker™ staining using established protocols (Grieshammer et
al., 2005; Lu et al., 2006a).Results
Expression of FGF receptors in postnatal mammary glands
We ﬁrst surveyed expression of the four FGF receptor tyrosine
kinase genes, Fgfr1, Fgfr2, Fgfr3 and Fgfr4, by RNA in situ hybridization
to determine which of these genes might function during postnatal
branching of the murine mammary gland. In sections through
mammary glands of pubertal wild-type mice at 5 weeks of age, we
Fig. 2. Consequences of MMTV-Cre-mediated inactivation of Fgfr2 in mammary epithelium. (A–H) The mammary branching tree at the postnatal stages indicated, as revealed by
Carmine Red staining of glands in wholemount. (A, C, E, G) glands from control (M-Cre;Fgfr2ﬂ/+) mice; (B, D, F, H) glands frommutant (M-Cre;Fgfr2ﬂ/Δ) mice. Insets in panels A and B
show high-magniﬁcation views of the rudimentary ductal tree (area in dashed box). (C–F) Arrowheads indicate TEBs at the tips of invading mammary epithelium. Arrows indicate the
extent of ductal penetration in the fat pad. (I, J) Quantitative comparisons of ductal penetration and branch point formation between control and mutant glands. At 5 weeks, ductal
penetration measurements were 6.0±1.4 (control, n=5) and 4.5±1.7 (mutant, n=6); at 7 weeks, the measurements were 14.6±2.2 (control, n=4) and 9.1±3.2 (mutant, n=4); at
12 weeks, they were 16.8±2.2 (control, n=8) and 16.0±2.9 (mutant, n=12). Measurements of branching points were 1.8±0.3 (control) and 0.9±0.2 (mutant) at 5 weeks, 1.3±0.1
(control) and 0.9±0.2 (mutant) at 7 weeks, and 1.4±0.1 (control) and 1.3±0.1 (mutant) at 12 weeks. Values shown are the mean±SD for each data point: ⁎⁎Pb0.0005; ⁎Pb0.05,
unpaired, two-tailed Student's t test. Scale bars: 2.5 mm. Abbreviation: LN, lymph node.
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and in the ductal epithelium (data not shown). In contrast, no Fgfr3
(Figs. 1D, D′) or Fgfr4 (Figs. 1E, E′) RNA was detected.
Since Fgfr2 appeared to be expressed at a substantially higher
level than Fgfr1, we further characterized Fgfr2 expression and aimed
our experiments at determining its function in the postnatal mam-
mary gland. Using immunoﬂuorescence microscopy, we detected
FGFR2 protein in the mammary epithelium from 2 to 14 weeks of age
(Figs. 1F–H‴, data not shown). At 5 weeks, a majority of cells in the
TEB, the interior body cells and the surrounding layer of cap cells,
were positive for FGFR2 (Fig. 1F). Co-staining with an antibody
against smooth muscle actin (SMA), which labels ﬁlaments in the
cytoplasm of cap cells and a few body cells of the TEB (Fig. 1F′),
showed that FGFR2 was primarily located in the nuclei of TEB cells
(Fig. 1F‴), as has been observed previously in TEBs and Sertoli cellprecursors in the testis (Schmahl et al., 2004). FGFR2 protein was
present in the luminal epithelium in mammary glands from pubertal
(5 weeks) females, where it was mainly nuclear, and from mature
(10 weeks) females, where it was mainly in the cytoplasm and at the
cell surface (Figs.1G,G‴, H,H‴). In addition, FGFR2wasdetected in a few
basal cells, where it was mostly nuclear and did not overlap with SMA
signals (Figs. 1G‴, H‴). Taken together, these expression data suggest
that FGFR2 functions during postnatal branchingmorphogenesis and in
the ductal epithelium of the adult mammary gland.
Mammary branching morphogenesis is delayed when Fgfr2 is
inactivated by MMTV-Cre
Since mice homozygous for an Fgfr2 null allele die at midgestation
(Xu et al., 1998; Yu et al., 2003), we used a conditional knock-out
81P. Lu et al. / Developmental Biology 321 (2008) 77–87strategy to eliminate Fgfr2 function after birth via Cre-mediated
recombination. We found that the MMTV-Cre transgene (M-Cre) we
employed (Wagner et al., 2001) functioned in mammary epithelium
by at least postnatal day 3 (data not shown). Male mice carrying one
copy of M-Cre and heterozygous for an Fgfr2 null allele, Fgfr2Δ (Yu etFig. 3. Analysis of Fgfr2 genetic mosaics produced byMMTV-Cre-mediated recombination. Im
distal mammary glands frommice at 14 weeks. (A–A″) control (M-Cre;Fgfr2ﬂ/+;Rﬂ/+) and (B–B″
and the red channel (A′, B′) shows FGFR2 protein expression. Note that FGFR2 expression
expression is mosaic in both control (A) andmutant (B) epithelium, and FGFR2 and β-GAL exp
from control and mutant #4 mammary glands were examined for these experiments. Scal
indicated. The dashed boxes in panels C–F demarcate the portions of the branching trees that
In all glands, β-GAL expressionmarks cells derived from those inwhichMMTV-Cre-mediated
present in TEBs of mutant mammary glands at 7 weeks (J, n=10). Note in panel F that at 7 w
whereas panel L shows that at 14 weeks (n=14) many cells in that region are β-GAL-positive.
in the mutant glands at 7 weeks; it was 84% of that in the control glands (8.9 mm±1.7 vs. 10
examined at each stage. Scale bars: 2.5 mm. (M–P) Sections through TEBs in mammary gland
with nuclear fast red. (M, N) control (M-Cre;Fgfr2ﬂ/+;Rﬂ/+) and (O, P) mutant (M-Cre;Fgfr2ﬂ/Δ;R
restricted to the body cells at 5 weeks (M, O). Scale bars: 50 μm.al., 2003), were crossed with females homozygous for an Fgfr2
conditional allele, Fgfr2ﬂ (Yu et al., 2003) to generate control (M-Cre;
Fgfr2ﬂ/+) andmutant (M-Cre;Fgfr2ﬂ/Δ) female mice. We then examined
mammary gland development in these animals at several critical
stages (Fig. 2).munoﬂuorescence assays for co-expression of β-GAL and FGFR2 on frozen sections from
)mutant (M-Cre;Fgfr2ﬂ/Δ;Rﬂ/+) glands. The green channel (A, B) shows β-GAL expression
is ubiquitous in control epithelium (A′), and mosaic in mutant epithelium (B′). β-GAL
ression aremutually exclusive in themutant epithelium (B–B″). Seven different sections
e bars: 10 μm. (C–L) Assays for β-GAL activity in wholemounts of glands at the stages
are shown at higher magniﬁcation in insets in panels C and D or in separate panels (G–J).
recombination occurred. Only a few β-GAL-positive cells (arrowheads, see also 3P) were
eeks there are few β-GAL-positive cells in the distal epithelium of the mutant glands,
Note that in this series of experiments, ductal penetrationwas also signiﬁcantly delayed
.6 mm±0.6, Pb0.01, unpaired, two-tailed Student's t test). 10–15 mammary glands were
s at the stages indicated, assayed for β-GAL activity in wholemount and counterstained
ﬂ/+) glands. At least 5 TEBs were examined for each stage. Note Cre activity was primarily
82 P. Lu et al. / Developmental Biology 321 (2008) 77–87At 3 weeks after birth, we observed a rudimentary ductal tree in
themutant glands that was not obviously different from that observed
in control glands (Figs. 2A, B). However, in pubertal mice at 5 weeks,
when vigorous mammary branching is occurring, we noticed a defect
in the branching tree in mutant glands (Figs. 2C, D). In comparison to
control glands, mammary ducts in mutant glands penetrated 75% of
the normal distance into the fat pad (Fig. 2I) and formed half as many
branch points (Fig. 2J). Ductal penetration was also delayed in the
mutants at 7 weeks (Figs. 2E, F, I, J). Despite the initially retarded
invasion, the ducts in mutant glands eventually completely inﬁltrated
the mammary fat pad by 12 weeks, which is ∼3 weeks after branching
morphogenesis is normally complete, although ductal branches were
slightly sparser than in control glands at this stage (Figs. 2G–J).
Together, the above data suggest that branching morphogenesis is
delayed, but not blocked, in the mutant glands due to loss of FGFR2
function in mammary epithelium.
Fgfr2 null cells are at a competitive disadvantage to Fgfr2 heterozygous
cells during branching morphogenesis in mosaic mammary glands
One potential explanation for the mutant phenotype that we
observed may relate to the observation that MMTV-Cre functions
incompletely in mammary epithelium (Wagner et al., 2001). As a
result, M-Cre;Fgfr2ﬂ/Δ mutant mammary glands may contain a
mixture of Fgfr2 null and Fgfr2 heterozygous cells, the latter of
which might continue ductal invasion in the pubertal glands. To test
this hypothesis, we employed a reporter allele, R26Rﬂ, that expresses
lacZ when it has undergone Cre-mediated recombination (Soriano,
1999). We ﬁrst produced a line of mice homozygous for both Fgfr2ﬂ
and R26Rﬂ (Fgfr2ﬂ/ﬂ;Rﬂ/ﬂ), and then crossed females of this line with
male mice that were carrying MMTV-Cre and were heterozygous for
the Fgfr2Δ allele, to generate control (M-Cre;Fgfr2ﬂ/+;Rﬂ/+) and mutant
(M-Cre;Fgfr2ﬂ/Δ;Rﬂ/+) progeny.
To determinewhether R26Rﬂ and Fgfr2ﬂ loci are equally susceptible
to Cre-mediated recombination and thus whether lacZ expression
accurately reports the conversion of Fgfr2ﬂ to an Fgfr2Δ allele, we
analyzed the expression of β-GAL and FGFR2 protein by immuno-
ﬂuorescence on frozen sections from both control and mutant adult
mammary glands. We found that mammary epithelium in the distalFig. 4. Analysis of Fgfr2 heterozygote/null genetic mosaics produced by Adenovirus Cre-med
ductal tree developed for 8 weeks from donor mammary epithelial cells harvested from
adenovirus-Cre (see Materials and methods). Asterisks indicate the transplantation sites in t
demarcate the regions shown at higher magniﬁcation in the corresponding panels (C–E). (F
shown only for the region demarcated by the dashed box (F) in panel B, demonstrates that the
positive/Fgfr2 null cells. 10 transplanted glands were examined for each genotype. Scale barglands was composed of a mixture of β-GAL-positive and β-GAL-
negative cells (Figs. 3A, B). As expected, co-staining for FGFR2 protein
in control glands showed that FGFR2 was present in all luminal
epithelial cells (Figs. 3A′, A″), since even those inwhich recombination
of the Fgfr2ﬂ allele had occurred still carried a wild-type Fgfr2 allele.
By contrast, in the mutant glands, we observed mosaicism of FGFR2-
negative and FGFR2-positive cells (Fig. 3B′), since recombination of
the Fgfr2ﬂ allele should render the cells Fgfr2 null. Importantly, among
the luminal epithelial cells all the β-GAL-positive cells were also
FGFR2-negative, indicating that recombination of both R26Rﬂ and
Fgfr2ﬂ had occurred in the same cells; conversely, all the β-GAL-
negative luminal epithelial cells were also FGFR2-positive (Fig. 3B″),
indicating that no Cre-mediated recombination of either allele had
occurred in those cells. These results thus indicate that β-GAL-staining
is an accurate reporter of Fgfr2 null cells in mutant glands.
Next, we assessed the mammary glands from control and mutant
mice for β-GAL activity at various postnatal stages to determine the
distribution of cells in which Cre-mediated recombination had
occurred. At 3 weeks, before the onset of pubertal branching, β-
GAL-positive cells were evenly distributed throughout the epithelial
branching network, including ducts and tips, in both control and
mutant mammary glands (Figs. 3C, D). At 5 weeks, there was a similar
number of, or perhaps slightly more, β-GAL-positive cells in control
than in mutant TEBs, which were primarily body cells, and subtending
ducts (immediately adjacent to the TEBs) (Figs. 3M, O). At 6 and
7 weeks, β-GAL-positive cells were evenly dispersed throughout the
entire branching network in control glands (Figs. 3E, G, H, N), whereas
inmutant glands theyweremostly restricted to the proximal region of
the branching network (Figs. 3F, I, J). Near the invasion front (red
dotted line in Fig. 3F), and at some distance behind it, there were very
few β-GAL-positive cells in the mutant gland (Fig. 3J). Analysis of
thinner sections showed that the few β-GAL-positive cells present
primarily lined the lumen and did not occupy the leading edge of
multi-layered TEBs (Fig. 3P). Together, these data indicate that during
branching morphogenesis in the mutant glands, the β-GAL-positive/
Fgfr2 null cells are at a competitive disadvantage to β-GAL-negative/
Fgfr2 heterozygous cells and consequently do not participate in the
formation of the distal branching network. By contrast, β-GAL-
positive/Fgfr2 heterozygous cells in control mosaic glands areiated recombination. (A–E) Assays for β-GAL activity in mammary glands in which the
(A) control Fgfr2+/+;Rﬂ/ﬂ and (B) mutant Fgfr2ﬂ/ﬂ;Rﬂ/ﬂ female mice and infected with
he recipient fat pads from which donor cells grew out. Dashed boxes in panels A and B
) The glands were stained with Yo-Yo1 to illuminate the branching tree; This staining,
re aremany epithelial branches in a region of the gland that contains virtually no β-GAL-
s: 2.5 mm.
83P. Lu et al. / Developmental Biology 321 (2008) 77–87functionally equivalent/similar to and can compete with β-GAL-
negative/Fgfr2 wild-type cells to give rise to the whole mammary
epithelium.
Interestingly, we found that, by 14 weeks, the distal epithelium of
the mutant glands contained β-GAL-positive cells throughout the
ductal tree, thus resembling the control glands (Figs. 3K, L). The most
plausible explanation of this ﬁnding is that there are consecutive
round(s) of Cre-mediated recombination in the mature glands. The
effect of this would be to convert many of the β-GAL-negative/Fgfr2
heterozygous cells that participated in mammary branching into β-
GAL-positive/Fgfr2 null cells. This hypothesis is consistent with the
reports that the MMTV promoter driving Cre expression is responsive
to progesterone (Otten et al., 1988; von der Ahe et al., 1985) and thusFig. 5. Cell proliferation as assessed by BrdU incorporation assays in Fgfr2 genetic mosaics pro
β-GAL and BrdU on frozen sections of control and mutant mammary glands at 4 weeks. S
percentage of BrdU-positive cells in the β-GAL-negative and β-GAL-positive cell populations
total of 1533 cells from 11 TEBs and 1341 cells from 19 ducts were counted in control glands; a
Values are the mean±SD for each data point. ⁎Pb0.00005, paired, two-tailed Student's t tes
between β-GAL-negative (FGFR2 heterozygous) and β-GAL-positive (FGFR2 null) cells in TECre may be expressed cyclically in concert with progesterone surges
during the estrus cycle.
We also examined the mutant mammary glands during pregnancy
and lactation. For these experiments, adult females older than
14 weeks of age were crossed with wild-type males. Interestingly,
fewer alveolar units were found in mutant mammary glands than in
control glands at pregnancy day 14 (Supplementary Figs.1A, B). Assays
for β-GAL enzymatic activity showed that β-GAL-positive/Fgfr2 null
cells were evenly distributed throughout the mutant glands and were
present in the alveoli (Supplementary Figs. 1C, D). The mammary
epithelium in mutant glands was able to differentiate and produce
milk during lactation despite being considerably less dense than in
control glands (Supplementary Figs. 1E–H, data not shown).duced byMMTV-Cre-mediated recombination. (A–D) Immunoﬂuorescent co-staining of
amples were counterstained with To-Pro3. (E and F) A quantitative comparison of the
in TEBs and ducts of mammary glands from control (E, n=3) andmutant (F, n=4) mice. A
nd 3052 cells from 16 TEBs and 1798 cells from 20 ducts were counted in mutant glands.
t. Note that the only signiﬁcant difference in percent BrdU-positive cells was observed
Bs. Scale bars: 50 μm.
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2008), these data suggest that Fgfr2 also plays a role during pregnancy
and/or lactation.
Fgfr2 null cells persist in the proximal branches of the mammary tree
One possible explanation for the competitive disadvantage of Fgfr2
null cells is that FGFR2 functions as a survival factor and Fgfr2 null
cells are therefore eliminated by cell death during mammary
branching. If this is the case, the presence of Fgfr2 null cells in the
luminal epithelium of the proximal mammary gland may have
resulted from recent recombination events due to consecutive round
(s) of MMTV-Cre activity and therefore these cells may have
participated in duct formation when they were still Fgfr2 hetero-
zygotes. To test directly whether Fgfr2 null cells can contribute to and
survive in luminal epithelium, we performed experiments using a
replication incompetent adenovirus encoding the Cre gene, which acts
only once (He et al., 1998; Naylor et al., 2005; Rijnkels and Rosen,
2001; Rohlmann et al., 1996; Seagroves et al., 2003). Mammary
epithelial cells were harvested from Fgfr2+/+;Rﬂ/ﬂ and Fgfr2ﬂ/ﬂ;Rﬂ/ﬂ
female mice at 5 weeks of age and infected with the recombinant
adenovirus in culture. Cre protein produced in those cells that were
successfully infected (∼50–70% of treated cells) should convert the
Fgfr2ﬂ allele into an Fgfr2 null allele and activate β-GAL expression
from the R26R allele. The mosaic donor cell population was then
transplanted into fat pads of immunologically deﬁcient mice at
3 weeks of age, from which endogenous epithelium had been
removed. 8 weeks after transplantation, we harvested mammary
glands and examined the distribution of β-GAL-positive cells in the
regenerated ductal tree.
We found that the donor cells successfully repopulated the fat pad
and established a mature mammary tree. In control glands, β-GAL-
positive cells were distributed evenly throughout the entire branching
tree (Figs. 4A, C, D). In mutant glands, we observed a distribution of β-
GAL-positive cells similar to that observed in M-Cre;Fgfr2ﬂ/Δ;Rﬂ/+
glands at 7 weeks (Fig. 4B, compare with 3F). Thus thereweremany β-
GAL-positive cells in the luminal epithelium in the proximal branching
tree, near and distal to the site of donor cell injection (asterisk in Fig.
4B), and their number decreased in progressively more distal regions,
with virtually none near the invasion front (Figs. 4B, E). These results
indicate that in the mammary gland Fgfr2 null cells are at aFig. 6. Model of FGFR2 function during postnatal branching morphogenesis in the mamma
mammary glands at 3 and 6 weeks. Fgfr2 heterozygous cells are colored yellow and wild-typ
ducts, during postnatal development. Fgfr2 promotes cell proliferation of in TEB cells to ensur
genetic mosaic mammary glands. Fgfr2 heterozygous cells are colored yellow and Fgfr2 null
TEBs undergo rapid cell proliferation and active epithelial invasion following the onset of pub
longer contribute to the distal ductal network.competitive disadvantage to Fgfr2 heterozygous cells, and that Fgfr2
null cells are viable for at least 8 weeks.
We investigated whether Fgfr2 null cells were dying by performing
a TUNEL assay on mammary glands at 4 weeks after birth
(Supplementary Fig. 2). Overall, there were few dying cells at this
stage, which was conﬁrmed by an alternative cell death analysis based
on Lysotracker™ staining (Grieshammer et al., 2005; Lu et al., 2006a)
(data not shown). We did not observe any obvious difference in the
frequency of dying β-GAL-negative and β-GAL-positive cells in TEBs of
the control (M-Cre;Fgfr2ﬂ/+;Rﬂ/+, n=3) and mutant (M-Cre;Fgfr2ﬂ/Δ;
Rﬂ/+, n=4) glands, although the very low rate of dying cells increased
in the ducts in mutant glands. Together, these data suggest that FGFR2
does not function as a survival factor in TEBs and that Fgfr2 null cells
persist in mature ducts.
FGFR2 promotes cell proliferation in TEBs during postnatal branching
If FGFR2 is necessary for normal cell proliferation in the mammary
gland, then this would explain why Fgfr2 null cells are out-competed
by neighboring Fgfr2 heterozygous cells. We investigated this by
determining the percent BrdU-labeled cells in control (M-Cre;Fgfr2ﬂ/+;
Rﬂ/+, n=3) and mutant (M-Cre;Fgfr2ﬂ/Δ;Rﬂ/+, n=4) glands at 4 weeks of
age (Fig. 5). We found no signiﬁcant difference in percent BrdU-
labeled, β-GAL-negative and BrdU-labeled, β-GAL-positive cells in
either TEBs or ducts in control glands (Figs. 5A, B, and E), suggesting
that Fgfr2 heterozygous cells are similar to wild-type cells with regard
to their proliferative capacity. By contrast, in mutant glands, the
frequency of BrdU-labeled, β-GAL-negative cells was twice as high as
BrdU-labeled, β-GAL-positive cells in TEBs (Figs. 5C, F). In the ducts,
we detected no difference in percent BrdU-labeling between β-GAL-
negative and β-GAL-positive cells (Figs. 5D, F). Together, these results
demonstrate that Fgfr2 promotes cell proliferation in TEBs during
postnatal branching morphogenesis and in its absence, Fgfr2 negative
cells proliferate more slowly than their heterozygous neighbors in
TEBs.
Discussion
In this study, we provide direct genetic evidence that FGFR2
functions during mammary branching morphogenesis. By analyzing
genetic mosaic mammary glands composed of a mixture of Fgfr2 nullry gland. (A) Schematic representations of primary branches in control genetic mosaic
e cells are colored blue. Fgfr2 is expressed in mammary epithelium, including TEBs and
e normal branchingmorphogenesis but is not required in the proximal ducts. (B) Mutant
cells are colored purple. Fgfr2 null cells survive and persist in proximal ducts, but when
erty, Fgfr2 null cells are rapidly depleted. Once diluted out of the TEB, Fgfr2 null cells no
85P. Lu et al. / Developmental Biology 321 (2008) 77–87and Fgfr2 heterozygous epithelial cells, we show that Fgfr2 null cells
are out-competed by their Fgfr2 heterozygous neighbors and are
depleted from the TEBs at the epithelial invasion front. This compe-
titive disadvantage is due, at least in part, to reduced proliferation of
Fgfr2 null cells. Thus, FGFR2 functions in the highly proliferative
TEBs for normal ductal morphogenesis, but is not required in mature
ducts. Unlike EGF receptor (EGFR), which primarily functions in the
stroma, our study points to the importance of FGFR2 signaling acting
in the mammary epithelium to promote epithelial morphogenesis in
the postnatal mammary gland.
FGFR2 contributes to mammary branching by stimulating cell
proliferation in TEBs
Because complete loss of Fgfr2 function results in midgestation
lethality due to a defective placenta (Xu et al., 1998; Yu et al., 2003),
we used a conditional gene inactivation approach to assess Fgfr2
function in the postnatal mammary gland. We took advantage of the
inefﬁciency of the MMTV-Cre transgene to produce animals with
mammary glands that were mosaic for Fgfr2 null and Fgfr2
heterozygous cells, and in which the Fgf2 null cells were marked
by LacZ expression from the recombined R26Rﬂ reporter allele. We
found that pre-pubertal mammary glands had a substantial number
of Fgfr2 null cells distributed evenly in the developing ductal tree.
However, at the onset of puberty, when branching morphogenesis
accelerates and becomes dependent on rapid proliferation of cells in
the TEBs, Fgfr2 null cells were rapidly diluted out of the TEBs. This
dilution apparently occurred because the Fgfr2 null cells proliferate
more slowly than the neighboring heterozygous cells. Once absent
from the TEB, Fgfr2 null cells no longer contributed to the distal
ductal network (Fig. 6). Together, our data suggest that the delay in
ductal penetration in the mutant glands likely resulted from the
presence of a substantial number of Fgfr2 null cells early on,
whereas the preponderance of Fgfr2 heterozygous cells in the TEBs
at later stages resulted in the eventual completion of branching
morphogenesis.
Our results show that Fgfr2 null cells that are incorporated in the
ductal tree can survive for many weeks. This result is interesting
because in other developmental contexts (Grieshammer et al., 2005;
Lu et al., 2008; Poladia et al., 2006), including the branching tips of
Fgfr2 null kidney epithelium (Zhao et al., 2004), a loss of FGF signaling
can lead to cell death. It is possible that in the mammary epithelium,
survival of the Fgfr2 null cells is stimulated by signaling via FGFR1,
which we have shown is co-expressed with FGFR2 in mammary
epithelial cells. Additionally, their survival may depend on other
receptor tyrosine kinases (RTKs), including ERBB2 (Jackson-Fisher et
al., 2004) and insulin-like growth factor-I receptor (IGF-IR) (Bonnette
and Hadsell, 2001), which are expressed in mammary epithelium and
are required for ductal branching. Thus, RTKsmayhave a combinatorial
function in regulating epithelial cell survival in the mammary gland.
Our analysis of cell proliferation in mammary glands at 4 weeks
showed that in TEBs, where many cells are dividing, the percent Fgfr2
null cells actively engaged in proliferationwas approximately half that
of their Fgfr2 heterozygous neighbors. Given such a differential, it is
easy to understand why the Fgfr2 null cells are rapidly diluted out of
the TEBs. In contrast, in ducts, where many fewer cells proliferate, the
percent Fgfr2 null cells actively engaged in proliferation was similar to
that of their Fgfr2 heterozygous neighbors. Thus, the results of our
mosaic analysis indicate that in the normal mammary gland FGF
signaling functions in TEB cells to stimulate them to proliferate
frequently enough to generate both cells at the tips of branching
epithelium and cells in the subtending duct. These results are
consistent with a recent report demonstrating, by using a dominant-
negative approach, that function of FGF receptors, presumably
FGFR2b, is required for cell proliferation and TEB maintenance in the
mammary gland (Parsa et al., 2008).These data are also similar to arecent study showing that Fgfr2 inactivation causes a reduction of cell
proliferation in prostate epithelium (Lin et al., 2007). Since the Fgfr2
null cells were still able to proliferate in mammary and prostate
glands, a conclusion from these studies and ours is that other signaling
cascades besides FGF signaling must contribute to the overall
proliferation rate. Candidates for these signals include HGF/MET,
IGF1/IGFR and WNT pathways, a lack of each of which causes defects
in mammary gland development [reviewed in Sternlicht et al., 2006;
Wiseman and Werb, 2002].
Our mosaic analysis allowed us to directly compare cell behaviors
of Fgfr2 heterozygous cells with wild-type cells in the same control
mosaic glands. Unlike in mutant glands, Fgfr2 heterozygous cells in
control glands were able to compete with wild-type cells and
contribute evenly to the mammary ductal tree along the proximal–
distal axis. Indeed, cell proliferation and cell death analyses further
demonstrated that Fgfr2 heterozygous cells and wild-type cells are
indistinguishable in both aspects. These results are consistent with
previous studies showing that Fgfr2 heterozygosity is sufﬁcient to
sustain development ofmultiple vertebrate organs, including embryo-
nic mammary gland (Mailleux et al., 2002), limb (Lu et al., 2008), and
kidney (Zhao et al., 2004). Together, we conclude that one copy of
Fgfr2 is sufﬁcient to support normal mammary gland branching
morphogenesis.
Cre-mediated mosaic analysis facilitates phenotypic analysis
Genetic mosaic analysis is a powerful complement to conventional
knock-out and conditional null strategies for studying gene function
and for analyzing cell lineages and cell behaviors during development
(Ciruna and Rossant, 2001; Shakya et al., 2005; Tam and Rossant,
2003). In mice, this approach has generally involved producing
chimeras by combining null with wild-type or heterozygous embryos.
However, one limitation of this method is that an early requirement
for the gene of interest in a given lineage may result in exclusion of
mutant cells from that lineage and thus prevent an assessment of the
gene's function at later stages (Rossant and Spence, 1998). This
limitation can be overcome by producing chimeras not with null
embryos, but with embryos in which the gene of interest will be
conditionally inactivated by Cre-mediated recombination. In this
study we have used an alternative approach in which we created
genetic mosaic embryos using the MMTV-Cre transgene or adeno-
virus-Cre. This technique combined the advantages of genetic mosaic
and conditional knock-out analyses and enabled us to determine that
Fgfr2 functions during branching morphogenesis in the postnatal
mammary gland. We were also able to demonstrate that although
Fgfr2 is expressed in both TEBs and ducts, it is essential in the TEBs,
where the majority of cell proliferation is ongoing, but is not required
in ducts, where many fewer cells are proliferating.
Our study underscores two features of the MMTV-Cre transgene
that limit its usefulness for conventional tissue-speciﬁc loss- or gain-
of-function analyses in the mammary gland. First, the Cre transgene
does not function in all cells. Thus, in situations when mutant cells
proliferate more slowly or are at some other competitive disadvan-
tage, like the Fgfr2 null cells in this study, compensation by cells in
which Cre-mediated recombination did not occur may obscure the
null mutant phenotype. On the other hand, in cases where mutant
cells have a signiﬁcant competitive advantage over cells in which Cre-
mediated recombination does not occur, the mutant phenotype
should be readily observable (Li et al., 2002). Second, due to
progesterone-responsiveness of the promoter, the MMTV-Cre trans-
gene presumably undergoes consecutive round(s) of activation,
which can result in Cre-mediated recombination after the process
of interest has occurred and thus confound the interpretation. It is
important to bear these caveats in mind when the MMTV-Cre
transgene is used for tissue-speciﬁc analysis of gene function in the
mammary gland.
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morphogenesis
The data reported here and in other studies demonstrate that a
key function of FGFR2 in vertebrate branching morphogenesis is to
regulate cell proliferation and/or survival. However, other functions
of FGF signaling in this process must also be considered. Of
particular interest in this context are the studies of the role of
FGF signaling during branching morphogenesis in the Drosophila
tracheal and air sac systems, where FGF signaling regulates cell
migration, cell rearrangement and cell shape changes (Cabernard et
al., 2004; Ghabrial et al., 2003; Metzger and Krasnow, 1999; Uv et
al., 2003). Unlike the tracheal system, in which there is no cell
proliferation when the cells are undergoing migration and branch-
ing, the ﬂy air sac system resembles vertebrate organs in that cell
proliferation and cell death are concomitant with branching
morphogenesis (Cabernard et al., 2004). Using genetic mosaic
analysis, recent studies have shown that cells lacking FGF signaling
activities fail to migrate and thus do not stay at the leading edge
during branching morphogenesis of the ﬂy trachea (Ghabrial and
Krasnow, 2006; Sutherland et al., 1996) and air sacs (Cabernard and
Affolter, 2005).
Therefore, it remains a possibility that in genetically mosaic
mammary glands, cell behaviors other than proliferation also
contribute to FGFR2-dependent cell competition during branching
morphogenesis. Indeed, FGF signaling regulates an array of cell
behaviors in mammary gland organotypic cultures (Ewald et al.,
2008) and in various vertebrate developmental settings (Bottcher and
Niehrs, 2005; Ciruna and Rossant, 2001; Coumoul and Deng, 2003;
Mariani et al., 2008; Shim et al., 2005; Xian et al., 2005). Future studies
should address whether FGFR2 regulates such cell behaviors,
especially cell fate determination, cell adhesion and migration, during
branching morphogenesis of the mammary gland.
Epithelial–stromal interactions during mammary branching
morphogenesis
The Fgfr2 gene produces two receptor isoforms, FGFR2b and
FGFR2c, which are generated by alternative splicing (Itoh and
Ornitz, 2004). In various vertebrate tissues, FGFR2b has been shown
to be primarily expressed in the epithelium and to respond to
mesenchyme-derived FGFs, such as FGF7 and FGF10, whereas
FGFR2c is expressed in the mesenchyme and responds to
epithelium-derived FGFs (Ornitz et al., 1996; Orr-Urtreger et al.,
1993; Peters et al., 1992; Yu et al., 2000). As mentioned earlier,
FGF10–FGFR2b signaling is required for embryonic mammary gland
development (Mailleux et al., 2002). In addition, Fgf10 continues to
be expressed in the stroma of the postnatal gland (Kouros-Mehr
and Werb, 2006; Pedchenko and Imagawa, 2000). Thus, although
our study does not directly address this issue, it is likely that the
effects we observed in the mutant mammary glands were due to
the absence of the Fgfr2b isoform.
In addition to FGF signaling, several other molecular pathways
are involved in epithelium–stroma interactions during branching
morphogenesis in the postnatal mammary gland. For example,
epithelium-derived amphiregulin (AREG), a member of the EGF
family, promotes (Luetteke et al., 1999; Sebastian et al., 1998), and
TGF-β1 inhibits (Ewan et al., 2002; Mailleux et al., 2007) mammary
branching by targeting the stroma (Cheng et al., 2005; Pollard,
2001; Serra and Crowley, 2005). Interestingly, TGF-β1 has been
shown to inhibit Fgf10 expression in several experimental settings,
including ﬁbroblast (Beer et al., 1997), lung (Lebeche et al., 1999)
and prostate epithelial cultures (Tomlinson et al., 2004). Whether
or how TGF-β1 or EGFR regulates production and activity of
stromal FGFs during mammary branching morphogenesis remains
to be determined.Acknowledgments
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